Pharmacovigilance (PV) inspections are becoming more rigorous each year as regulators strengthen their expectations around safety governance, data integrity, and oversight. As we move into 2026, the UK MHRA and EU authorities are placing stronger emphasis on end-to-end visibility, evidence-based processes, and traceability across all safety activities.
Many organisations still fall into avoidable mistakes that not only lead to inspection findings but also reveal deeper system weaknesses. Below are the five most critical PV inspection mistakes companies continue to make, why they matter, and how organisations can proactively avoid them.
Also Read: Why Your Pharmacovigilance System Master File Could Fail Your Next Inspection
1. Weaknesses in the PSMF and Safety Governance Documentation
The Pharmacovigilance System Master File (PSMF) is a central focus of inspections. Inspectors rely on it to understand the maturity, control, and transparency of your safety system.
Common issues include:
- Outdated or inconsistent PSMF sections
- Missing or unclear roles and responsibilities
- Annexes that are incomplete or not maintained
- Processes that do not reflect real operational practice
- Incorrect or outdated metrics
Why this matters
Any inconsistency between the PSMF and real operations raises concerns about oversight, documentation discipline, and governance structure. Even small errors can suggest broader system weaknesses.
How to avoid it in 2026
- Conduct regular PSMF health checks
- Align content with current operational workflows
- Maintain clear ownership for annexes
- Ensure alignment between QPPV oversight, SOPs, and system controls
- Preserve audit trails for every update
2. Incomplete or Non-Compliant Safety Data Management
Regulators expect complete accuracy, traceability, and auditability across the entire safety lifecycle.
Common failures include:
- Missing intake documentation
- Incorrect seriousness assessments
- Delays in case processing
- Inconsistent or incorrect MedDRA coding
- Limited oversight of partners or affiliates
- Gaps in reconciliation or quality check evidence
Why this matters
Data quality issues undermine confidence in the entire PV system. Inspectors view data inconsistencies as signals of weak process control, inadequate training, or insufficient oversight of external partners.
How to avoid it in 2026
- Conduct regular case quality reviews
- Implement structured intake and triage protocols
- Strengthen vendor oversight and reconciliation processes
- Calibrate coding practices through periodic reviews
- Maintain clear audit trails for every action taken on a case
3. Outdated or Poorly Implemented SOPs and Work Instructions
Regulators expect companies to operate according to accurate, current, and well-controlled procedures.
Common issues include:
- SOPs that do not reflect updated tools or technologies
- Work instructions copied from other functions without adaptation
- SOPs that lack detail on how activities must be performed
- Inadequate training evidence or competency assessments
- Gaps between written procedures and real operational practice
Why this matters
Outdated or poorly implemented procedures signal weak process governance. Inspectors quickly identify misalignment between documented processes and real-world activities.
How to avoid it in 2026
- Conduct annual SOP reviews
- Maintain document control within a centralised system
- Ensure training is role based and well documented
- Map operational workflows directly to controlled procedures
- Validate compliance through internal audits and routine checks
4. Insufficient QPPV Oversight and Documentation Evidence
Regulators continue to increase their focus on QPPV oversight and accountability.
Common observations include:
- Lack of documented review or approval by the QPPV
- Limited evidence of QPPV-led governance meetings
- Delayed communication during critical safety events
- Unclear reporting structures to senior leadership
- Insufficient safety performance metrics
Why this matters
Inspectors must be able to clearly see that the QPPV has authority, visibility, and direct involvement in safety decision making. Weak evidence of oversight is often treated as a major finding.
How to avoid it in 2026
- Maintain clear documentation of all QPPV activities
- Record governance meetings with actions, owners, and timelines
- Provide timely access to safety data and performance metrics
- Define escalation pathways in a transparent manner
- Strengthen two way communication between the QPPV and leadership
5. Lack of End-to-End Inspection Readiness and Cross-Functional Alignment
Effective PV inspections rely on smooth coordination between multiple functions, including Regulatory, Medical Affairs, Clinical, Quality, Commercial, and external partners.
Typical issues include:
- Slow or inconsistent document retrieval
- Inaccurate or conflicting responses during interviews
- Gaps in supporting evidence
- Lack of preparation or mock inspection training
- Limited awareness of inspection expectations across functions
Why this matters
Inspectors not only assess documentation but also examine how well the organisation demonstrates control. Miscommunication or slow responses immediately raise concerns.
How to avoid it in 2026
- Conduct mock inspections and rehearsal interviews
- Establish a clear inspection readiness plan
- Develop standard response templates for teams
- Train staff to respond based only on verified information
- Improve cross-functional document coordination
Building Inspection Ready Pharmacovigilance Systems
Avoiding these five critical mistakes requires a proactive mindset, strong governance culture, and continuous improvement. Organisations that invest early in documentation discipline, oversight, and cross functional alignment will be best positioned for smooth PV inspections in 2026.
Proactive inspection readiness does more than reduce the risk of findings. It strengthens the entire pharmacovigilance system. Companies that consistently review and refine their procedures, workflows, and controls demonstrate reliability, transparency, and a strong commitment to patient safety.
How Quality and Vigilance LTD Supports You in 2026
With increasing regulatory expectations, organisations need structured, reliable, and evidence based safety governance.
Quality and Vigilance LTD provides comprehensive assistance including:
- PV system gap assessments
- PSMF reviews and governance alignment
- Safety data quality audits
- Vendor oversight frameworks
- SOP and documentation optimisation
- QPPV oversight support
- Inspection readiness and mock audits
Our team supports organisations in strengthening safety systems, reducing risk, and achieving full inspection readiness across the pharmacovigilance lifecycle.